Advance Market Commitments: Demand-Side Capital Mobilization

In rooms where capital and climate are meant to meet, a familiar sequence plays out. Everyone agrees the money exists. Everyone agrees the problem is real. Then nothing moves.

The usual fix is a subsidy: a grant, a tax credit, a first-loss tranche that absorbs the early hit. Supply-side support has its place, and in young ecosystems it can be the only lever that works. It also has a failure mode anyone who has run a corporate innovation budget will recognise. The pilot succeeds, the champion who sponsored it rotates to a new role, no follow-on budget appears, and the project dies of neglect.

An older instrument comes at the problem from the other end, and it has a track record most impact tools would envy. It is called an advance market commitment.

What an advance market commitment is

An advance market commitment is a binding promise, made before a product exists, to buy a defined quantity of it at a defined price if someone builds it to spec. The buyer does not fund the research and does not pick the winner. The buyer commits to the demand.

A supply-side subsidy answers “who will pay to build this?” An AMC answers “if we build it, will anyone buy it?” For a founder or a corporate R&D team weighing a long-horizon bet, uncertainty about the market often kills the decision before uncertainty about the science does. A guaranteed market changes what a rational team is willing to attempt.

The idea was formalised for vaccines in the mid-2000s. The Center for Global Development’s 2005 report Making Markets for Vaccines, with economist Michael Kremer among its architects, argued that poor-country diseases attracted little private R&D because there was no paying market at the end of the road, not because the science was harder. Fix the market failure at the demand end and supply would follow, the report said. (Center for Global Development)

The case that proved it

In 2009 Italy, the United Kingdom, Canada, Russia and Norway, together with the Bill & Melinda Gates Foundation, committed US$1.5 billion to the first advance market commitment, for pneumococcal vaccines. Pneumococcal disease was one of the leading causes of child mortality, and vaccines suited to low-income countries had lagged for years behind the versions sold in wealthy markets. The AMC guaranteed a subsidised price for a set volume, provided manufacturers produced a vaccine meeting a published target profile. (Gavi)

Manufacturers invested in capacity because the demand was contracted rather than hoped for. Roll-out to low-income countries happened years earlier than the historical lag would have predicted, and the vaccine reached tens of millions of children. The science already existed; the AMC paid for the factories.

The climate version is already running

In April 2022 Stripe, Alphabet, Shopify, Meta and McKinsey launched Frontier, an advance market commitment for permanent carbon removal, committing close to a billion dollars to purchase removal through 2030 before most of the technologies that would deliver it were commercially proven. (Frontier) Durable carbon removal had been stuck with no buyers because there was no supply, and no supply because there were no buyers. A contracted demand signal was what broke that.

The pandemic produced the same shape. Operation Warp Speed’s advance purchase agreements committed governments to buy COVID-19 vaccines at scale before efficacy was known, so manufacturers could build capacity in parallel with trials instead of after them. When the binding constraint is market risk rather than technical risk, guaranteeing the purchase moves faster than financing the lab.

Where it breaks

An AMC is not free money and it does not fit every problem.

It needs a deliverable specific enough to write into a contract. Pneumococcal vaccines had a target product profile; carbon removal has measurable tonnes. A vague social outcome cannot anchor an AMC because “impact” cannot go into a purchase order. It also needs a buyer whose promise holds over the full time horizon, which is where the champion-rotation problem comes back. A commitment that evaporates when a procurement lead changes jobs or a four-year political cycle turns over is an aspiration with a letterhead.

It does not replace early-stage capital either. An AMC pulls a technology across the commercialisation gap; it does not fund the first proof of concept. Demand guarantees and patient equity do different jobs, and the practical question is which constraint is binding for a given technology at a given stage, and which instrument is aimed at it.

The point for the people in the room

When senior investors, corporates and operators gathered in Tokyo for Tech for Impact Summit, the catalytic-capital conversation kept returning to this distinction. Supply-side subsidy divided the room: some argued first-loss structures jump-start a young market, others that they stigmatise a healthy one. Demand-side instruments drew far less disagreement. Advance procurement and advance market commitments were named repeatedly as the tools that had created categories, against the usual backdrop of pilots that succeed and then die for want of a follow-on order.

“Mobilise more capital for impact” is a sentence everyone in the room can agree with, and it moves nothing. The conversation that produces a decision is narrower: for a particular technology stuck at a particular stage, which instrument unblocks it, who has to make the binding commitment, and how that commitment survives the tenure of the person who signs it.

Tech for Impact Summit returns to Tokyo on 18–19 May 2027, an invitation-only gathering of leaders across business, policy and finance, built for conversations at the table rather than from the stage. You can request an invitation at tech4impactsummit.com/apply.